Search results for " Mab" in Articles / App Notes
Article
Process Development: 2020 Reflections and 2021 Possibilities
On the note of mAbs, another area of interest in 2020 was strategies to improve the mAb manufacturing process and streamline overall bioprocessing operations. mAb manufacturing productivity can be gre…
Article
Reimagining Affordable Biosimilars
A typical study for complex biologics, such as mAbs, includes the following components: assessment of acute toxicity (two-weeks to one month) via single- and multi-dose studies, including evaluation o…
Article
Flexible Facilities for Viral Vector Manufacturing
Increased biosafety requirement
Viral-vector manufacturing has some similarities to mAb manufacturing, but also some differences. “Compared to mAbs, viral vectors are much larger, more complex mol…
Article
Best Practices for Selecting a Top-Quality Cell Line
Once scaled up, the mAbs should be 5 to >10 g/L in the bioreactor. “This high level of productivity must also be maintained for more than 60 generations at the high-density and in the defined media co…
Article
Biopharmaceutical Process Development: 2018 Lessons and 2019 Predictions
…ing of Biologic Drug Products
• Tools and Solutions for Separation of Charged mAb Variants
• Modern Manufacturing Key to More Effective Vaccines
• Evaluation of Performance of a Dis…
Article
Unifying Continuous Biomanufacturing Operations
Benchtop systems, then, could be sufficient for the commercial production of some mAbs. Integrated continuous bioprocessing is already regularly being achieved in small research labs, according to Bon…
Article
Improvements in Protein A Chromatography
Alternative technologies like CEX capture or precipitation often provide lower purity and require more mAb-specific development.
What future directions would you like to see in the development o…
Article
A Risk-Based Genetic Characterization Strategy for Recombinant CHO Cell Lines Used for Clinical and Commercial Applications
Reichert, MAbs. 7 (1), pp. 1–8 (2015).
2. S.D. Wijesuriya, R.L. Cotter, and A.H. Horwitz, Protein Expr. Purif. 92 (1), pp. 14–20 (2013).
3. D. Guo et al., Biotechnol. Bioeng. 107 (1), pp. 163–17…
Article
Biopharma in 2015: A Year for Approvals and Innovations
First Hospira Biosimilar mAb Approved in West Europe, Randi Hernandez, Pharmaceutical Technology, Feb. 17, 2015.
3. Global & USA BioSimilar Market Analysis Report 2015-2021, Research and Markets, h…
Article
Modular Manufacturing Platforms for Biologics
…n also be operational 12 months after project initiation, Almhem says, and there are several modular mAb facilities that are already in operation. In fact, modular systems are best for mAbs and are l…